Viracta Therapeutics (VIRX) Competitors $0.0098 0.00 (0.00%) As of 07/25/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIRX vs. SHPH, TNFA, SCNI, ATXI, CDT, PBM, SLRX, ASLN, BPTH, and EVFMShould you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Shuttle Pharmaceuticals (SHPH), TNF Pharmaceuticals (TNFA), Scinai Immunotherapeutics (SCNI), Avenue Therapeutics (ATXI), Conduit Pharmaceuticals (CDT), Psyence Biomedical (PBM), Salarius Pharmaceuticals (SLRX), ASLAN Pharmaceuticals (ASLN), Bio-Path (BPTH), and Evofem Biosciences (EVFM). These companies are all part of the "pharmaceutical products" industry. Viracta Therapeutics vs. Its Competitors Shuttle Pharmaceuticals TNF Pharmaceuticals Scinai Immunotherapeutics Avenue Therapeutics Conduit Pharmaceuticals Psyence Biomedical Salarius Pharmaceuticals ASLAN Pharmaceuticals Bio-Path Evofem Biosciences Viracta Therapeutics (NASDAQ:VIRX) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends. Do institutionals and insiders hold more shares of VIRX or SHPH? 31.4% of Viracta Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. 10.7% of Viracta Therapeutics shares are owned by insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better earnings and valuation, VIRX or SHPH? Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViracta TherapeuticsN/AN/A-$51.06M-$1.10-0.01Shuttle PharmaceuticalsN/AN/A-$9.15M-$4.15-0.86 Is VIRX or SHPH more profitable? Shuttle Pharmaceuticals' return on equity of -1,203.10% beat Viracta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viracta TherapeuticsN/A -1,899.61% -114.21% Shuttle Pharmaceuticals N/A -1,203.10%-370.42% Which has more volatility and risk, VIRX or SHPH? Viracta Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of -1.08, indicating that its share price is 208% less volatile than the S&P 500. Does the media prefer VIRX or SHPH? In the previous week, Shuttle Pharmaceuticals had 2 more articles in the media than Viracta Therapeutics. MarketBeat recorded 2 mentions for Shuttle Pharmaceuticals and 0 mentions for Viracta Therapeutics. Shuttle Pharmaceuticals' average media sentiment score of 1.43 beat Viracta Therapeutics' score of 0.00 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Viracta Therapeutics Neutral Shuttle Pharmaceuticals Positive Do analysts prefer VIRX or SHPH? Viracta Therapeutics currently has a consensus price target of $1.75, suggesting a potential upside of 17,793.66%. Given Viracta Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Viracta Therapeutics is more favorable than Shuttle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viracta Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Shuttle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryViracta Therapeutics beats Shuttle Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRX vs. The Competition Export to ExcelMetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$389K$799.72M$5.59B$9.82BDividend YieldN/A4.84%4.60%4.11%P/E Ratio-0.011.1830.2125.67Price / SalesN/A26.58448.53106.03Price / CashN/A19.5637.7558.93Price / Book0.036.578.436.01Net Income-$51.06M-$4.39M$3.26B$264.94M7 Day PerformanceN/A3.12%3.90%2.65%1 Month PerformanceN/A-1.28%4.16%1.49%1 Year PerformanceN/A19.59%35.99%29.16% Viracta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRXViracta Therapeutics1.6475 of 5 stars$0.01flat$1.75+17,793.7%N/A$389KN/A-0.0120SHPHShuttle Pharmaceuticals1.7785 of 5 stars$3.63+3.7%N/AN/A$1.54MN/A-0.875Negative NewsShort Interest ↓Gap DownTNFATNF PharmaceuticalsN/A$0.11+5.7%N/AN/A$1.52MN/A-0.026Upcoming EarningsGap UpSCNIScinai Immunotherapeutics1.2875 of 5 stars$1.51+2.7%N/A-55.3%$1.47M$660K-0.1620Upcoming EarningsShort Interest ↑Gap DownATXIAvenue Therapeutics1.6186 of 5 stars$0.46+1.1%N/A-77.1%$1.46MN/A0.034CDTConduit Pharmaceuticals0.4164 of 5 stars$1.88+4.4%N/A-99.1%$1.44MN/A0.003Short Interest ↑Gap UpPBMPsyence Biomedical2.3472 of 5 stars$4.54+92.4%N/A-98.9%$1.34MN/A0.00N/AShort Interest ↓Gap UpHigh Trading VolumeSLRXSalarius Pharmaceuticals0.5067 of 5 stars$0.61-3.2%N/A-75.3%$1.34MN/A-0.1320News CoverageEarnings ReportGap UpASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330BPTHBio-Path0.8176 of 5 stars$0.14-4.9%N/A-89.7%$1.20MN/A0.0010Negative NewsShort Interest ↓Gap DownEVFMEvofem Biosciences1.738 of 5 stars$0.01+1.1%N/A-1.1%$1.08M$11.39M-0.01120News CoverageNegative NewsShort Interest ↓ Related Companies and Tools Related Companies SHPH Alternatives TNFA Alternatives SCNI Alternatives ATXI Alternatives CDT Alternatives PBM Alternatives SLRX Alternatives ASLN Alternatives BPTH Alternatives EVFM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRX) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access